Mechanisms of human drug-induced anaphylaxis

Pierre Bruhns, PhD^{1,2} and Sylvie Chollet-Martin, MD PhD^{3,4}

Authors' affiliations

¹ Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR 1222 INSERM, F-75015 Paris, France.

² DHU FIRE, Labex Inflammex, Université Paris Diderot Paris 7, F-75018 Paris, France.

³ Department “Auto-immunité et Hypersensibilités », DMU BioGeM, APHP, Hôpital Bichat, F-75018 Paris, France.

⁴ « Inflammation, microbiome and immunosurveillance” INSERM UMR 996, Faculté de Pharmacie, Université Paris-Saclay, F-92290 Châtenay-Malabry, France.

Sources of funding: none of the sources of funding have an interest in the subject matter or materials discussed in the submitted manuscript

Correspondence to: Pierre Bruhns, Unit of Antibodies in Therapy and Pathology, Department of Immunology, Institut Pasteur, 25 rue du Docteur Roux, 75015 Paris, France. E-mail: bruhns@pasteur.fr; Sylvie Chollet-Martin, Inflammation Chimioquinas et Immunopathologie, INSERM UMR S996, Faculté de Pharmacie, Université Paris-Saclay, 92290 Châtenay-Malabry, France. E-mail: sylvie.chollet-martin@universite-paris-saclay.fr

ABSTRACT

Drug-induced anaphylaxis is a hyperacute reaction affecting multiple organs that can be of fatal consequence. Its incidence is increasing, consistent with a global increased sensitization to various allergens and drugs in the population. Few risk factors and mechanisms have been identified from human studies due to the rarity of anaphylactic events and their unpredictability. This systemic reaction is caused by the rapid release of a large range of functionally diverse mediators, including histamine and platelet-activating factor as the main drivers identified. Mechanisms defined from models of experimental anaphylaxis identify drug-specific antibodies of the IgE and IgG class that link the drug to antibody receptors on multiple cell types, causing their activation and mediator release. In the case of drugs with peculiar chemical structures, antibodies may not be necessary as drug-binding receptors, like mas-related G-protein coupled receptor member X2, have been identified. This review describes the complex reaction leading to drug-induced anaphylaxis that can involve various antibody classes, various cell types - including mast cells, neutrophils, platelets, basophils, macrophages and monocytes -, their mediators and receptors that, importantly, can be implemented alone or in association to participate in the severity of the reaction.

KEY WORDS

Anaphylaxis; drugs; IgE; IgG; MRGPRX2; platelet activating factor; histamine; serotonin; mast cells; basophils; neutrophils; platelets

ABBREVIATIONS USED

cPLA2: cytosolic phospholipase A2
CD32A: human activating IgG receptor FcγRIIA
FcεRI: high-affinity receptors for the Fc portion of IgE
FcγR: receptors for the Fc portion of IgG
FcγR^{null} mice: mice deficient for FcγRI, FcγRIIB, FcγRIII and FcγRIV
Fcγ^{-/-} mice: mice deficient for the Fcγ-chain, lacking all activating IgG and IgE receptors
FcRn: neonatal IgG recycling receptor
IL-4: interleukin-4
LuLISA: luciferase-linked immunosorbent assay
Mrgprb2: Mas-related G-protein coupled receptor member b2
MRGPRX2: Mas-related G-protein coupled receptor member X2
NETs: neutrophil extracellular traps
NMBA: neuromuscular blocking agents
NSAIDs: nonsteroidal anti-inflammatory drugs
PAF: platelet-activating factor
PAF-R: PAF-receptor
PAF-AH: PAF-acetyl hydrolase
PEG: polyethylene glycol

MAIN TEXT

INTRODUCTION

Anaphylaxis is a hyperacute reaction that can be of fatal consequence. It is a systemic reaction caused by the rapid and systemic release of a large range of functionally diverse mediators affecting multiple organs. These mediators typically induce urticaria, vasodilatation, increased vascular permeability and vascular leakage, edema and bronchoconstriction, leading to a drop in arterial pressure, tachycardia, bronchospasm and digestive troubles. Death can be caused by the resulting cardiac failure and/or asphyxia or pulmonary edema following major bronchospasm. Anaphylactic reactions cannot, in general, be foreseen. Due to their life-threatening nature, they represent an emergency situation for the medical staff.

The more recent publications describe a world incidence of anaphylaxis in humans between 50 and 112 episodes per 100 000 person-years, and drug allergy mortality is estimated at 0.05–0.51 per million people/year¹. Interestingly, drug-induced anaphylaxis incidence is increasing, consistent with a global increased sensitization to various allergens in the population, including drugs². Almost 60% of fatal anaphylaxis cases have been attributed to drugs^{3, 4}. Due to their increasing availability, the anaphylaxis to mAbs jumped at an average rate of 0.77% of total anaphylaxis reports per year in the United States, from 2.00% in 1999 to 17.37% in 2019; it was the fastest increase observed among all the drugs responsible for anaphylaxis⁵. Surprisingly, very different drugs – whether considering chemical nature or structure, size, target, mode of action, biodistribution – lead to anaphylactic events with similar symptoms and consequences. The most frequent culprit drugs are antibiotics (mostly penicillin and cephalosporins), nonsteroidal anti-inflammatory drugs (NSAIDs), injected radiocontrast agents (iodinated contrast media and gadolinium), antineoplastic drugs, therapeutic antibodies and neuromuscular blocking agents (NMBA) used during surgery^{3, 4, 6}. Even more surprisingly, the size of most of these compounds are 100-1,000 times smaller than “classical” allergens - linked to allergic reactions to pollens, house dust mite, food allergens -, and due to this minimal size, these drugs would rather qualify as haptens (Figure 1): antibiotics, *e.g.* Penicillin 334 Da; Ciprofloxacin 331 Da; NSAIDs, *e.g.* Ibuprofen 206 Da, Diclofenac 296 Da; radiocontrast agents, *e.g.* Iodinated contrast media 613 Da; NMBA, *e.g.* Suxamethonium 361 Da, Rocuronium 530 Da. Their small size, allowing them to passively diffuse

systemically, could be interpreted as a common feature of drugs with anaphylactic potential. Nevertheless, drugs of radically larger sizes, proteins of 20-180 kDa including therapeutic antibodies, *e.g.* infliximab 149 kDa, cetuximab 152 kDa, or enzymes used for enzyme replacement therapy, *e.g.* glucocerebrosidase 60 kDa, and polymers 200-35,000 kDa contained in drug preparations like polyethylene glycol ^{7, 8} (Figure 1) that do not diffuse passively, are also reported to cause drug anaphylaxis with similar kinetics. Adding to the complexity, the route of administration of the drug responsible for anaphylaxis can be multiple: oral, infused, injected (intravenous, intradermal, subcutaneous, intramuscular). Concerning the inhalation route, some cases have been reported in asthmatic children using inhaled corticosteroids, probably related to milk protein traces ⁹. This variability in chemical nature, size, biodistribution of culprit drugs for anaphylactic events makes it difficult to envision a single mechanism responsible for anaphylaxis induction.

Evidence of the mechanisms responsible for anaphylaxis from human studies is scarce due to the rarity of anaphylaxis and its unpredictability, and thus of the very few prospective clinical studies performed so far. Similarities between local allergic reactions (*e.g.* skin rashes, edema) and low-grade systemic anaphylaxis has led to proposing mechanisms of allergic reactions as the basis of severe anaphylactic reactions also without solid evidence to support them. Thus, clinical research in anaphylaxis has mainly focused on accumulating evidence of an “allergic” mechanism, including presence of certain mediators (*e.g.* histamine), enzymes (*e.g.* tryptase) and antibodies (*e.g.* IgE) classically involved in local allergic reactions. If histamine, tryptase and allergen-specific IgE are rather biomarkers than actual triggers of the anaphylactic reaction, which may be induced by other mechanisms entirely, will be discussed herein. As an example, histamine is found at elevated levels during anaphylactic reactions and proposed as the main mediator of anaphylaxis, but antihistamines do not demonstrate efficacy on severe anaphylaxis symptoms. Below are summarized risk factors and evidence from human studies to propose that anaphylaxis is an integration of diverse mechanisms leading to systemic organ failure rather than, simply put, an extreme allergic reaction.

RISK FACTORS & EVIDENCE FROM HUMAN STUDIES

Few risk factors have been identified that increase the risk of developing a drug-induced anaphylactic event. Whereas sex remains a matter of debate with controversies on higher rates of drug-induced anaphylaxis in women ^{3,10}, old age has been linked to both an increased risk of severe reactions and a higher incidence ¹¹ with pre-existing cardiovascular morbidity being an important co-factor ⁴. Surprisingly, atopy and allergic status of the patients does not appear to be convincingly related to higher risk of drug-induced anaphylaxis ⁶, suggestive that different or additional mechanisms may be at play in ‘systemic’ anaphylaxis compared to more ‘local’ allergic reactions. Nevertheless, patients with mastocytosis, a disease characterized by the presence of high numbers of mast cells in various organs, have a high occurrence of anaphylaxis ¹², suggesting of a role of mast cells – the crucial effector cell of allergic reactions and inflammation ¹³ – in anaphylaxis.

Mast cells are notorious for the ability to quickly release histamine, the major mediator recognized in hypersensitivity reactions. Although antihistamines have not proven efficacious to prevent or treat severe anaphylaxis, intravenous administration of histamine in volunteers has been shown to reproduce most signs and symptoms of anaphylaxis, including cutaneous flushing, headache, airway obstruction, and transient hemodynamic changes, mainly evidenced by systemic hypotension and tachycardia ^{14,15}. Thus, histamine has the capacity to mediate the symptoms of anaphylaxis, but is clearly not the sole mediator involved. Vadas *et al* indeed reported in their landmark study in 2008 that platelet-activating factor (PAF) levels in serum were directly correlated, and the activity of its degrading enzyme, PAF acetylhydrolase, inversely correlated, with the severity of anaphylaxis ¹⁶. Their follow-up work ¹⁷ reported that histamine, PAF and tryptase, the major enzyme of mast cell secretory granules already identified as a biomarker for anaphylaxis ¹⁸, were all detected in serum of patients that underwent anaphylaxis of low- (grade 1), mild- (grade 2) and severe (grade 3) severity. However, serum concentrations of PAF and tryptase, but not histamine, correlated with anaphylaxis severity ¹⁷. PAF is an extremely lipid mediator that can activate a variety of cells that express the PAF-receptor (PAF-R), including endothelium, smooth muscle, and myeloid cells including mast cells. Thus, PAF could directly elicit the circulatory and respiratory symptoms of anaphylaxis while also eliciting the generation of other mediators involved in anaphylaxis propagation and severity. Intracutaneous injection or inhalation of PAF elicit symptoms resembling grade 1 anaphylaxis and bronchoconstriction ,

respectively, in human subjects ^{19, 20}. Even though deficiencies in the enzyme degrading PAF, PAF-acetylhydrolase (*i.e.* leading to high levels of PAF) have been correlated with respiratory deficiencies in asthmatic children ²¹, no study has linked it yet to anaphylaxis. Nevertheless PAF-acetylhydrolase activity inversely correlates with anaphylaxis severity, and can be used as its marker ^{16, 22}. In contrast to PAF, mast cell tryptase is not thought to elicit rapid responses that contribute to immediate manifestation of anaphylaxis, although its effects are only partially described ²³. Mast cells in the vicinity of an activated mast cell releasing tryptase have been reported to become activated in turn and to release histamine ²⁴. Tryptase is considered mainly a ‘practical’ marker of mast cell activation as it can be easily detected in serum ¹⁸. Altogether, these data suggest that among identified immediate mediators with potency to be anaphylaxis inducers, PAF, rather than histamine, is the contributor of the more severe forms of anaphylaxis (grade 3) and potentially of lethality (grade 4) when highly abundant systemically. More explorations of anaphylactogenic mediators (e.g. leukotrienes, prostaglandins) in human drug-induced anaphylaxis remains to be performed to understand fully the mechanisms leading to moderate and severe symptoms, or even to lethality.

Until recently, only one pathway had been universally accepted as the mechanistic explanation of anaphylaxis induction: the IgE antibody pathway. Antibodies of the IgE class are generated at in small quantities by B lymphocytes. Once produced, IgE antibodies have a very short half-life in circulation as they cannot be recycled by the IgG recycling receptor FcRn. Total IgE levels are thus only 50-200 ng/mL in healthy individuals but generally several fold higher in allergics, with patients having allergen-specific IgE levels up to 200ng/mL, particularly those that experienced anaphylactic events ²⁵. Direct evidence of the role of IgE in human anaphylaxis is based on transfer of purified human IgE in the skin of human volunteers that transferred allergen reactivity ²⁶ and several clinical trials using the anti-IgE therapeutic antibody omalizumab: one suggesting less spontaneous episodes of anaphylaxis in patients with mastocytosis ²⁷, others proposing anti-IgE therapy as an adjunct therapy for allergic desensitization, leading to fewer anaphylactic episodes ²⁸⁻³⁰.

Although the precise conditions for human B cells to start producing an IgE remain speculative and extrapolated from data obtained in animal models ³¹, recent human studies found evidence that

allergen-specific IgE B cells arise from mature B cells producing initially an allergen-specific IgG³². Although elusive, human circulating non-secreting IgE B cells, *i.e.* IgE memory B cells, as well as non-circulating IgE-secreting B cells, *i.e.* IgE plasma cells, have recently been identified (in extremely low numbers) in the blood and bone marrow, respectively, of allergic patients^{33, 34}. Indirectly supporting a role for these IgE-secreting cells located in the bone marrow in human anaphylaxis, bone marrow transplantation from allergic donors to non-allergic recipients has been reported in a few cases to transfer drug hypersensitivity, penicillin hypersensitivity for example (reviewed in³⁵). Although several donor cell types in the allograft may contribute to the transfer of hypersensitivity, specific penicillin IgE could be detected 3 months after transplant, supporting the likely importance of graft-associated IgE-producing B cells³⁶. This hypothesis is further supported by the observation that transplantation of livers from fatal anaphylaxis cases transferred food hypersensitivity (nuts or peanuts) to recipients with either detectable specific IgE or positive skin prick test (reviewed in³⁵). Of note, IgE-producing B cells related to food allergy have been identified in the gut, and arise most probably from mature B cells producing initially a food allergen-specific IgA³⁷. Wherever IgE is anatomically secreted - bone marrow, liver, gut - it has the unique ability to 'sensitize' human mast cells in tissue but also human basophils in blood, empowering them with the ability to react to a variety of specific targets, including allergens and drugs. This phenomenon, unique among antibody classes, relies on the IgE receptor FcεRI that these cells express constitutively. FcεRI is of such high-affinity that once bound an IgE remains on a mast cell for weeks³⁸. Upon penetration of a drug/allergen in the body, it will bind to IgE-sensitized cells, provoke FcεRI aggregation on their surface, leading to cell activation, degranulation and mediator release, including histamine, tryptase and PAF.

Although IgE may be responsible for many cases of anaphylaxis to drug or allergen, it may be undetectable in others³⁹. In such cases, the terms "anaphylactoid reactions" (*i.e.* anaphylaxis-like reaction) or "idiopathic anaphylaxis" (*i.e.* anaphylaxis of unclear trigger) may be applied. IgG antibodies are proposed as causative agents, and can be detected in some patients who react to NMBA⁴⁰, PEG⁴¹, therapeutic antibodies and other drugs (reviewed in⁴²). Although not proven, IgG antibodies could trigger activation of macrophages and other cells bearing Fcγ receptors, either directly inducing

anaphylaxis or acting in concert with IgE having the same specificity. Additionally, anaphylaxis-like reactions to certain drugs may be caused by direct interaction with Mas-related G-protein coupled receptor member X2 (MRGPRX2),^{43, 44} which is expressed at high level in primary human skin and synovial mast cells, but not in primary lung mast cells⁴⁵. Many drugs capable of directly inducing histamine release can bind and activate MRGPRX2⁴⁶ (Figure 2).

MECHANISMS IDENTIFIED IN EXPERIMENTAL ANAPHYLAXIS

Most animal models of systemic anaphylaxis are directly relevant to drug-induced anaphylaxis as they are based on the injection of a bolus of allergen/antigen/drug into a sensitized animal. Two main types of models are used. In passive systemic anaphylaxis, naive animals are directly injected with an anaphylactogenic mediator (e.g. histamine, PAF) or with antibodies thought to be responsible for anaphylaxis induction followed by a challenge with an allergen/antigen/drug in the next hours or days. In active systemic anaphylaxis, animals are exposed to low doses of an allergen/antigen/drug to induce an antibody response against that molecule followed by a challenge several weeks later. In the latter case, initial exposures can be performed in the presence or absence of an adjuvant. Surprisingly, models of active sensitization reveal that the presence or absence of adjuvant influences the principal mechanisms leading to anaphylaxis induction⁴⁷⁻⁴⁹. Thus, that each animal model of anaphylaxis, even each experimental protocol thereof, will draw a different picture of what pathways of anaphylaxis in humans may be (discussed in⁴²). Even though data may be considered conflicting between studies, animal models have provided an enlightened understanding of the multiple mechanisms at play that are, in our view, the current basis of human anaphylaxis exploration and dogma: antibodies of the IgE and/or IgG class to the culprit drug triggering multiple cell types through activating antibody receptors, or mast cell activating receptors directly triggered by some drugs, notably Mas-related G-protein coupled receptor member b2 (Mrgprb2), the mouse ortholog of human MRGPRX2.

Passive systemic anaphylaxis. Injection of histamine or PAF in mice leads to symptoms resembling systemic anaphylaxis that are dependent on the presence of histamine receptors or PAF receptor (PAF-R), respectively⁵⁰. Injection of allergen-specific IgE or allergen-specific IgG followed by allergen challenge (generally intravenous injection) hours to days later provokes systemic, sometimes

fatal, anaphylaxis that requires expression of FcεRI or IgG receptors (FcγR), respectively (reviewed in⁴⁷ and⁴⁸). Both IgE and IgG receptors require cross-linking to trigger cell activation, implying that multiple IgE or IgG molecules need to bind the same drug molecule, or that the drug has been haptenized onto a carrier molecule to allow multimeric interactions. Among mouse IgG subclasses allergen-specific IgG2a and IgG2b are potent inducers, whereas IgG1 is weak⁵¹, in line with its preferential binding to inhibitory mouse FcγR⁵² and its rather anti-inflammatory role in mice⁵³. Ciprofloxacin, an antibiotic of the fluoroquinolone family, can induce antibody independent anaphylaxis in mice. Mice lacking Mrgprb2 (the mouse orthologue of MRGPRX2) are protected from ciprofloxacin-induced anaphylaxis⁴⁴. As is the case for MRGPRX2 in humans, Mrgprb2 in mice is expressed almost exclusively on mast cells and is since considered a direct target of several drugs belonging to fluoroquinolones, NMBA (*e.g.* atracurium, rocuronium) chemical classes and cationic peptides⁴³. A novel mouse model allowing for the development of human mast cells expressing MRGPRX2 reported local mast cell degranulation after exposure to contrast agents, but did not investigate systemic reactions⁵⁴. Altogether passive models of anaphylaxis validate antibody classes IgE and IgG and their receptors, Mrgprb2 and mediators histamine and PAF as potential inducers of anaphylaxis in simplified models (Figure 2), but are not able to rank them or discriminate among them for their relevance in human anaphylaxis.

Active systemic anaphylaxis. Mice sensitized with allergen in the presence of adjuvants show detectable IgE and IgG specific for the allergen, and develop anaphylaxis upon allergen challenge (intravenous, gavage) with severity increasing with higher doses of allergen. Surprisingly, IgE-deficient or FcεRI-deficient mice were protected from some active anaphylaxis models, but not others, demonstrating that the ‘IgE pathway’ is not necessary in some models active systemic anaphylaxis (reviewed in⁴⁸,⁴² and⁵⁵). In contrast, mice lacking all activating IgG and IgE receptors (FcRγ^{-/-} mice) were resistant to anaphylaxis, as well as mice lacking only IgG receptors (FcγR^{null})⁵⁶⁻⁵⁸. Transgenic expression in FcγR^{null} mice of a single⁵⁹ or of multiple human FcγR^{57, 58} restored anaphylaxis, demonstrating the requirement of the ‘IgG pathway’ in severe active systemic anaphylaxis. Even though convincing animal studies on the potential contribution of the complement system to anaphylaxis are still lacking (discussed in⁴²), some compounds trigger complement component C3a production leading

to myeloid cell activation through their complement receptors and, thus, to PAF and histamine release⁶⁰. Mice deficient in either PAF-R or cytosolic phospholipase A2 (cPLA2) that is required for PAF generation (and, in the case of cPLA2, leukotriene and prostaglandin generation) had markedly reduced anaphylaxis symptoms^{50, 56}. PAF-R antagonists consistently strongly inhibited anaphylaxis symptoms and protected from lethality in different mouse models of active anaphylaxis, whereas antihistamines had moderate to negligible effects, unless in concert with PAF-R antagonists^{49, 51, 56, 61, 62}. Depending on the active systemic anaphylaxis model and/or the mouse strain used, tissue-resident mast cells and macrophages, and circulating basophils, monocytes and neutrophils have all been convincingly reported to be main (reviewed in^{48, 42} and⁵⁵). More recently platelets were added to this list through two independent reports using human activating IgG receptor FcγRIIA (CD32A) transgenic mice, proposing that platelets release pathogenic serotonin in response to FcγRIIA triggering on their surface by circulating IgG-antigen/allergen immune complexes (Figure 2)^{58, 63} that form following exposure to high amounts of antigen/allergen as is mostly the case in drug anaphylaxis. The abundance and systemic distribution of platelets suggests a plausible role in anaphylaxis. Because humans and non-human primates, but not rodents, express FcγRIIA⁵², the potential contribution of platelets in anaphylaxis models may be missed in mice lacking transgenic expression of FcγRIIA.

While animal studies suggest a diverse range of initiating pathways for anaphylaxis, demonstrating the contribution of each pathway in severe human anaphylaxis is challenging, since sampling of blood is typically undertaken after the reaction has occurred. Nevertheless, markers have been proposed to confirm the engagement of the IgE pathway (increase in interleukin-4 (IL-4) and soluble IL-4 receptor levels) and/or the IgG pathway (decrease in FcγR expression)⁶⁴, which have been reported to occur simultaneously in a mouse model of fatal anaphylaxis⁶¹. Our group demonstrated the reduced FcγR expression was a marker of the IgG pathway in passive and active mouse models of anaphylaxis^{51, 57} and in our recent clinical study on NMBA-induced anaphylaxis (described in the next section)⁴⁰. The diverse range of candidate effector cell types identified in animal studies makes their relative contribution difficult to comprehend in humans. The contributions from different cell types are

likely influenced by cell numbers, their capacities for activation, and the abundance of mediators generated per cell. Among circulating cells, platelets (150,000-450,000/ μ L) are ~70, ~700 and ~100,000-fold more abundant than neutrophils (2,500-6,000/ μ L), monocytes (200-600/ μ L) and basophils (1-3/ μ L). How these compare to mast cell and macrophage numbers is unclear as both cell types reside in various human tissues in which they differentiate into different subpopulations expressing different enzymes, receptors (including different IgG receptors and levels of MRGPRX2 for mast cells) and mediators^{65, 66}. Skin mast cell densities in humans vary depending on the anatomical location⁶⁷. Considering numbers only, platelets and neutrophils would probably largely dominate over mast cells and macrophages, whereas mast cells and basophils would likely be the dominant cell types activated through IgE and MRGPRX2-dependent pathways. Considering the high levels of specific IgG necessary for generating immune complexes with their target drug to trigger Fc γ Rs, compared to few specific IgE-bound Fc ϵ RI on sensitized mast cells and basophils necessary to trigger their activation (Figure 2), IgE would largely dominate over IgG⁶⁸. These considerations apply even more in anaphylaxis to ingested drugs/antigens that require the compound to reach circulation, as only a small fraction of the ingested compound is absorbed^{69, 70}. Solving this equation is next to impossible, but informs clinicians of the possibility that one, two or even three different pathways, involving different antibody classes (or none), different receptors and different cell types in circulation and tissue resident, may be at play simultaneously in a drug-induced severe anaphylactic reaction. This next section will propose a clinician's view on drug-induced anaphylaxis, taking NMBA-hypersensitivity as an example.

NMBA-INDUCED ANAPHYLAXIS EXEMPLIFIES MULTIPLE MECHANISMS AT PLAY

As emphasized above with the animal models, the possible mechanisms leading to anaphylaxis in human begin to be better understood, as more and more actors are evidenced at the cellular or soluble levels that can interact and define complex endotypes. The example we chose to describe in this section in detail is NMBA-induced anaphylaxis during the perioperative period as it may be representative of drug-induced severe anaphylaxis implicating several pathways that synergize to increase severity.

The incidence of perioperative anaphylaxis varies between the geographical locations with rates of 1 in 10,000-20,000 anesthesia procedures. For the 2011-2012 period, in 714 patients who experienced perioperative anaphylaxis in France, the most common cause was NMBA administration (60%)⁷¹. The classical IgE-dependent mechanism that involves basophil and mast cell degranulation has been clearly documented in various studies for several years, mainly using the morphine quaternary ammonium (QA) as a surrogate epitope of antibody responses to NMBA, even if one can be critical on this laboratory reagent, the only one commercially available so far⁷². Interestingly, the historical hapten concept has been recently revisited by its author, Dr Werner J Pichler, who postulates now that in the minutes following the re-exposure to a drug, a massive mast cell degranulation occurs in response to IgE cross-linking by non-covalent drug-carrier complex called “fake antigen”⁷³. However, concerning NMBAs, the absence of any sign of IgE-dependent immune activation despite evident clinical anaphylaxis in 10-20% of patients led us to test the hypothesis of an IgG-induced neutrophil activation, as we previously described in mouse models⁵⁶.

We prospectively conducted a multicenter study of 86 patients with suspected anaphylaxis to NMBAs during general anesthesia and 86 matched controls (age, sex, drug, type of surgery)⁴⁰. We found that circulating anti-QA IgE was undetectable in a large percentage of the patients, whereas anti-QA IgG levels were significantly increased as compared to matched controls. Moreover, both anti-QA IgE and IgG levels correlated with anaphylaxis severity. We then found that down-regulation of FcγRs (CD32A, CD16) at the neutrophil surface was also associated with reaction severity, suggesting that anti-QA specific IgG formed immune complexes with NMBA to rapidly activate circulating neutrophils. This was further supported by increased neutrophil expression of CD11b and CD66b, elevated circulating levels of degranulated elastase and decreased PAF-acetyl hydrolase (PAF-AH) activity related to PAF secretion. Moreover, high levels of neutrophil extracellular traps (NETs), detected as DNA-myeloperoxidase complexes, were found in severe patients as compared to mild patients and to controls. Altogether, using a large panel of neutrophil activation markers, we could confirm that, in human, an IgG-dependent neutrophil activation occurs during NMBA anaphylaxis with, or independently of, IgE-dependent mast cell/basophil activation (Figure 3).

Supporting anti-NMBA IgG contribution to anaphylaxis and our finding that IgG receptor CD32A-expressing platelets can induce anaphylaxis in animal models, platelet activation in the same patient cohort suffering from NMBA anaphylaxis was associated with anaphylaxis severity and was accompanied by a reduction in circulating platelet numbers⁵⁸. In order to better document IgG-mediated mechanisms in anaphylaxis, we isolated rocuronium-specific IgG from one patient and found that they could form immune complexes with rocuronium that could in turn activate neutrophils isolated from healthy controls, as evidenced by the activation of oxidative burst and NET release (Figure 3). These results reconcile clinical and experimental data on the role of IgE and IgG during anaphylaxis and can modify our biological diagnostic approaches to NMBA-induced anaphylaxis, even if skin tests remain major tools for IgE-mediated reactions. Indeed, we can now suggest to implement the classical biological evaluation of suspected NMBA anaphylaxis^{74, 75} by exploring both IgE- basophil and IgG- neutrophil pathways.

Exploration of NMBA-induced anaphylaxis for the determination of specific IgEs against QA (as a surrogate epitope of NMBAs) and against each independent NMBA (rocuronium, atracurium, suxamethonium) can be made using commercial (ImmunoCAP, ThermoFisher) or home-made techniques, but the specificity is not optimal, false positivity and numerous cross-reactivities are observed⁷⁶. The calculation of specific to total IgE ratio did not improve the biological diagnosis of rocuronium allergy⁷⁷. Sensitization to NMBAs might originate from exposure to other drugs or compounds that contain also a QA epitope, like pholcodine (a morphine derivative contained in anti-cough medications): indeed, anti-pholcodine IgE can be detected in NMBA hypersensitive patients⁷⁸. Altogether these recent studies emphasize the difficulties of correctly quantifying the circulating anti-NMBA IgEs. New methods are needed and we can assume that the recent luciferase-linked immunosorbent assay (Lu-LISA) that demonstrated 10-100-fold better sensitivity than ImmunoCAP for peanut allergen-specific IgE could be adapted to other allergens and drugs including NMBA-specific IgE detection, providing perhaps enhanced sensitivity and specificity⁷⁹. In addition to anti-NMBA specific IgE, we now recommend, using similar techniques, to assay anti-NMBA specific IgG to increase the understanding of our clinical findings reported in 2019⁴⁰.

Assays to detect soluble mediators can be used to invoke mechanisms involved in anaphylaxis. Histamine and tryptase measurements, routinely used to confirm an anaphylactic reaction, reflect the activation of mast cells and, in the case of histamine, basophils. An elevated level of serum tryptase remains one of the very best markers of anaphylaxis. However, the level of tryptase at baseline (after resolution of the anaphylactic reaction) is required to calculate the acute tryptase levels using the following algorithm: tryptase levels are acute if $>[1.2 \times \text{baseline tryptase}] + 2 \mu\text{g/L}$ ⁸⁰. Baseline levels of tryptase are elevated in patients with mastocytosis (reflecting increased mast cell burden), and are associated with an increased risk of recurrent perioperative anaphylaxis⁸¹. As noted previously, human mast cells strongly express MRGPRX2 (which is also expressed more weakly by basophils in humans⁸²). MRGPRX2 can directly bind a number of drugs leading to mast cell activation and mediator release such as tryptase⁴⁴, meaning that elevated circulating tryptase levels at the initial phase of anaphylaxis can thus been generated by IgE- or MRGPRX2-dependent mast cell activation, or both. Initially the list of drugs activating MRGPRX2 included NMBA's atracurium and rocuronium among others, but conflicting results have placed this assumption under debate^{83, 84}. The ability and importance of rocuronium-induced MRGPRX2 activation is under evaluation, investigating effects of MRGPRX2 mutations^{85, 86}.

Both blood basophils and neutrophils can be studied *ex vivo* in the patients in order to improve diagnosis. The basophil activation test (BAT) is a useful tool to document NMBA anaphylaxis⁸⁷ that needs to be performed 4-6 weeks after the episode. This flow cytometry-based *ex vivo* assay can be adapted to other NMBA's⁸⁸. The versatility of BAT testing may make it an increasingly utilized tool in the diagnosis of NMBA-induced anaphylaxis. Additionally, elastase levels (using ELISA) and DNA-MPO levels (markers of increased netosis) may be useful for detecting neutrophil activation during anaphylaxis (Figure 3)⁸⁹. We can propose that a simple phenotypic study such as CD11b and CD66b expression, monitored over the course of a clinical reaction in parallel with tryptase, can document a potential specific anti-NMBA IgG-induced neutrophil activation at the time of the reaction in case of the presence of specific IgG.

CONCLUSION AND THERAPEUTIC AVENUES

Drug-induced anaphylaxis is: 1) a very severe clinical reaction that needs to be rapidly and extensively documented and diagnosed by adequate biological tools, 2) a complex reaction that can involve various cell types, mediators, receptors and intracellular pathways that can be activated alone or in association (Figure 2); NMBA-induced anaphylaxis being an ideal example.

Recent human clinical data proposed even further possible mechanisms in addition to MRGPRX2, exemplified by the role of contact system via factor XII activation and bradykinin release in some penicillin-induced anaphylaxis⁹⁰, or after heparin injection and severe hypotension due to oversulfated chondroitin sulfate contamination⁹¹. Explorations outside of basophil activation, *i.e.* neutrophil, platelet and monocyte activation, and of anti-drug IgE, *i.e.* presence of anti-drug IgG^{40, 41, 92}, should increase in clinical research to improve our understanding of anaphylaxis and define markers for its endotypes. Because many anaphylactic reactions to drugs happen at first exposure, identifying potential cross-reactivities is of major importance to discourage use of some drugs in potentially susceptible patients; hypersensitivity to the oligosaccharide alpha-gal as a consequence of tick bites leading to cetuximab anaphylaxis is a good example⁹³. In contrast, sensitization to some cereal and peach allergens (Lipid Transfer Protein) are high risk factors to NSAIDs anaphylaxis, without any cross-reactivity identified⁹⁴.

The first line treatment of any type of anaphylaxis, whatever the mechanism, is adrenaline (epinephrine). As far as therapeutic tools are concerned, the avoidance of the drug is the only efficient action when possible. If not possible, anaphylaxis might be prevented by pre-treating patients with the anti-IgE antibody omalizumab as it is known to be useful in drug desensitization⁹⁵. Anti-drug therapy to prevent IgE engagement might also be considered: allergen desensitization by anti-cat allergen antibody therapy has indeed been reported already⁹⁶, and might be transposed to drugs⁹⁷. Anti-drug therapy to capture the drug remains a poorly explored avenue to remove quickly the culprit drug and thereby arrest the ongoing anaphylactic reaction: attempts have been described in NMBA-induced anaphylaxis⁹⁸ due to the existence of a rocuronium and vecuronium capture reagent, sugammadex, but remains debated⁹⁹⁻¹⁰¹. Unfortunately, a significant number of (IgE-mediated) sugammadex-induced anaphylactic reactions have been described¹⁰²⁻¹⁰⁴, making this particular therapeutic compound non ideal to explore drug capture as a therapy for drug-induced anaphylaxis. Novel anti-drug therapies need

444 to be developed to understand the potential of drug capture to reduce anaphylaxis severity or even to
445 stop an ongoing anaphylactic reaction.
446

ACKNOWLEDGMENTS

This work was supported by the Institut Pasteur, the Institut National de la Santé et de la Recherche Médicale (INSERM) and by the European Research Council (ERC)–Seventh Frame-work Program (ERC-2013-CoG 616050) and a *Contrat Local d’Interface* to PB of the Assistance Publique des Hôpitaux de Paris (AP-HP).

REFERENCES

1. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. *World Allergy Organ J* 2020; 13:100472.
2. Tanno LK, Demoly P. Epidemiology of anaphylaxis. *Curr Opin Allergy Clin Immunol* 2021.
3. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. *J Allergy Clin Immunol* 2014; 134:1318-28 e7.
4. Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal Anaphylaxis: Mortality Rate and Risk Factors. *J Allergy Clin Immunol Pract* 2017; 5:1169-78.
5. Yu RJ, Krantz MS, Phillips EJ, Stone CA, Jr. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS). *J Allergy Clin Immunol Pract* 2020.
6. Kuruvilla M, Khan DA. Anaphylaxis to drugs. *Immunol Allergy Clin North Am* 2015; 35:303-19.
7. Sellaturay P, Nasser S, Ewan P. Polyethylene Glycol-Induced Systemic Allergic Reactions (Anaphylaxis). *J Allergy Clin Immunol Pract* 2020.
8. Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. *Clin Exp Allergy* 2016; 46:907-22.
9. Savvatanos S, Giavi S, Stefanaki E, Siragakis G, Manousakis E, Papadopoulos NG. Cow's milk allergy as a cause of anaphylaxis to systemic corticosteroids. *Allergy* 2011; 66:983-5.
10. Banerji A, Rudders S, Clark S, Wei W, Long AA, Camargo CA, Jr. Retrospective study of drug-induced anaphylaxis treated in the emergency department or hospital: patient characteristics, management, and 1-year follow-up. *J Allergy Clin Immunol Pract* 2014; 2:46-51.
11. Clark S, Wei W, Rudders SA, Camargo CA, Jr. Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals. *J Allergy Clin Immunol* 2014; 134:1125-30.
12. Schuch A, Brockow K. Mastocytosis and Anaphylaxis. *Immunol Allergy Clin North Am* 2017; 37:153-64.
13. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. *Nat Rev Immunol* 2007; 7:93-104.
14. Vigorito C, Russo P, Picotti GB, Chiariello M, Poto S, Marone G. Cardiovascular effects of histamine infusion in man. *J Cardiovasc Pharmacol* 1983; 5:531-7.
15. Kaliner M, Sigler R, Summers R, Shelhamer JH. Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses. *J Allergy Clin Immunol* 1981; 68:365-71.
16. Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. *N Engl J Med* 2008; 358:28-35.
17. Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. *J Allergy Clin Immunol* 2013; 131:144-9.

- 498 18. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator
499 of mast-cell activation in systemic anaphylaxis and mastocytosis. *N Engl J Med* 1987;
500 316:1622-6.
- 501 19. Basran GS, Page CP, Paul W, Morley J. Platelet-activating factor: a possible mediator of
502 the dual response to allergen? *Clin Allergy* 1984; 14:75-9.
- 503 20. Cuss FM, Dixon CM, Barnes PJ. Effects of inhaled platelet activating factor on
504 pulmonary function and bronchial responsiveness in man. *Lancet* 1986; 2:189-92.
- 505 21. Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, et al. Characterization
506 of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between
507 deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic
508 children. *J Clin Invest* 1988; 82:1983-91.
- 509 22. Pravettoni V, Piantanida M, Primavesi L, Forti S, Pastorello EA. Basal platelet-activating
510 factor acetylhydrolase: prognostic marker of severe Hymenoptera venom anaphylaxis.
511 *J Allergy Clin Immunol* 2014; 133:1218-20.
- 512 23. Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance.
513 *Anaesthesia* 2004; 59:695-703.
- 514 24. He S, Gaca MD, Walls AF. A role for tryptase in the activation of human mast cells:
515 modulation of histamine release by tryptase and inhibitors of tryptase. *J Pharmacol*
516 *Exp Ther* 1998; 286:289-97.
- 517 25. Platts-Mills TAE, Schuyler AJ, Erwin EA, Commins SP, Woodfolk JA. IgE in the diagnosis
518 and treatment of allergic disease. *J Allergy Clin Immunol* 2016; 137:1662-70.
- 519 26. Ishizaka K, Ishizaka T, Richter M. Effect of reduction and alkylation on allergen-
520 combining properties of reaginic antibody. *J Allergy* 1966; 37:135-44.
- 521 27. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab
522 for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. *J*
523 *Allergy Clin Immunol* 2007; 119:1550-1.
- 524 28. Nadeau KC, Kohli A, Iyengar S, DeKruyff RH, Umetsu DT. Oral immunotherapy and anti-
525 IgE antibody-adjunctive treatment for food allergy. *Immunol Allergy Clin North Am*
526 2012; 32:111-33.
- 527 29. Boni E, Incorvaia C, Mauro M. Dose-dependence of protection from systemic reactions
528 to venom immunotherapy by omalizumab. *Clin Mol Allergy* 2016; 14:14.
- 529 30. MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab
530 facilitates rapid oral desensitization for peanut allergy. *J Allergy Clin Immunol* 2017;
531 139:873-81 e8.
- 532 31. Davies JM, Platts-Mills TA, Aalberse RC. The enigma of IgE+ B-cell memory in human
533 subjects. *J Allergy Clin Immunol* 2013; 131:972-6.
- 534 32. Looney TJ, Lee JY, Roskin KM, Hoh RA, King J, Glanville J, et al. Human B-cell isotype
535 switching origins of IgE. *J Allergy Clin Immunol* 2016; 137:579-86 e7.
- 536 33. Croote D, Darmanis S, Nadeau KC, Quake SR. High-affinity allergen-specific human
537 antibodies cloned from single IgE B cell transcriptomes. *Science* 2018; 362:1306-9.
- 538 34. Asrat S, Kaur N, Liu X, Ben LH, Kajimura D, Murphy AJ, et al. Chronic allergen exposure
539 drives accumulation of long-lived IgE plasma cells in the bone marrow, giving rise to
540 serological memory. *Sci Immunol* 2020; 5.
- 541 35. Khan F, Hallstrand TS, Geddes MN, Henderson WR, Jr., Storek J. Is allergic disease
542 curable or transferable with allogeneic hematopoietic cell transplantation? *Blood*
543 2009; 113:279-90.

- 544 36. Walker SA, Riches PG, Wild G, Ward AM, Shaw PJ, Desai S, et al. Total and allergen-
545 specific IgE in relation to allergic response pattern following bone marrow
546 transplantation. *Clin Exp Immunol* 1986; 66:633-9.
- 547 37. Hoh RA, Joshi SA, Lee JY, Martin BA, Varma S, Kwok S, et al. Origins and clonal
548 convergence of gastrointestinal IgE(+) B cells in human peanut allergy. *Sci Immunol*
549 2020; 5.
- 550 38. Kinet JP. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology.
551 *Annu Rev Immunol* 1999; 17:931-72.
- 552 39. Laroche D, Chollet-Martin S, Leturgie P, Malzac L, Vergnaud MC, Neukirch C, et al.
553 Evaluation of a new routine diagnostic test for immunoglobulin E sensitization to
554 neuromuscular blocking agents. *Anesthesiology* 2011; 114:91-7.
- 555 40. Jonsson F, de Chaisemartin L, Granger V, Gouel-Cheron A, Gillis CM, Zhu Q, et al. An
556 IgG-induced neutrophil activation pathway contributes to human drug-induced
557 anaphylaxis. *Sci Transl Med* 2019; 11.
- 558 41. Zhou ZH, Stone CA, Jr., Jakubovic B, Phillips EJ, Sussman G, Park J, et al. Anti-PEG IgE in
559 anaphylaxis associated with polyethylene glycol. *J Allergy Clin Immunol Pract* 2020.
- 560 42. Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. *J*
561 *Allergy Clin Immunol* 2016; 137:1674-80.
- 562 43. Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, Furuno M, et al. Immunoglobulin
563 E-independent activation of mast cell is mediated by Mrg receptors. *Biochem Biophys*
564 *Res Commun* 2006; 349:1322-8.
- 565 44. McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. Identification of a
566 mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature* 2015;
567 519:237-41.
- 568 45. Varricchi G, Pecoraro A, Loffredo S, Poto R, Rivellese F, Genovese A, et al.
569 Heterogeneity of Human Mast Cells With Respect to MRGPRX2 Receptor Expression
570 and Function. *Front Cell Neurosci* 2019; 13:299.
- 571 46. Lagunoff D, Martin TW, Read G. Agents that release histamine from mast cells. *Annu*
572 *Rev Pharmacol Toxicol* 1983; 23:331-51.
- 573 47. Finkelman FD. Anaphylaxis: lessons from mouse models. *J Allergy Clin Immunol* 2007;
574 120:506-15; quiz 16-7.
- 575 48. Gillis CM, Gouel-Chéron A, Bruhns P. Anaphylaxis (Immediate Hypersensitivity): From
576 Old to New Mechanisms. *Encyclopedia of Inflammatory Diseases* 2015.
- 577 49. Balbino B, Sibilano R, Starkl P, Marichal T, Gaudenzio N, Karasuyama H, et al. Pathways
578 of immediate hypothermia and leukocyte infiltration in an adjuvant-free mouse model
579 of anaphylaxis. *J Allergy Clin Immunol* 2017; 139:584-96 e10.
- 580 50. Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S, et al. Impaired anaphylactic
581 responses with intact sensitivity to endotoxin in mice lacking a platelet-activating
582 factor receptor. *J Exp Med* 1998; 187:1779-88.
- 583 51. Beutier H, Gillis CM, Iannascoli B, Godon O, England P, Sibilano R, et al. IgG subclasses
584 determine pathways of anaphylaxis in mice. *J Allergy Clin Immunol* 2017; 139:269-80
585 e7.
- 586 52. Bruhns P. Properties of mouse and human IgG receptors and their contribution to
587 disease models. *Blood* 2012; 119:5640-9.
- 588 53. Strait RT, Posgai MT, Mahler A, Barasa N, Jacob CO, Kohl J, et al. IgG1 protects against
589 renal disease in a mouse model of cryoglobulinaemia. *Nature* 2015; 517:501-4.

54. Mencarelli A, Gunawan M, Yong KSM, Bist P, Tan WWS, Tan SY, et al. A humanized mouse model to study mast cells mediated cutaneous adverse drug reactions. *J Leukoc Biol* 2020; 107:797-807.
55. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. *J Allergy Clin Immunol* 2017; 140:335-48.
56. Jönsson F, Mancardi DA, Kita Y, Karasuyama H, Iannascoli B, Van Rooijen N, et al. Mouse and human neutrophils induce anaphylaxis. *J Clin Invest* 2011; 121:1484-96.
57. Gillis CM, Jonsson F, Mancardi DA, Tu N, Beutier H, Van Rooijen N, et al. Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in mice. *J Allergy Clin Immunol* 2017; 139:1253-65 e14.
58. Beutier H, Hechler B, Godon O, Wang Y, Gillis CM, de Chaisemartin L, et al. Platelets expressing IgG receptor FcγRIIA/CD32A determine the severity of experimental anaphylaxis. *Sci Immunol* 2018; 3.
59. Jönsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, et al. Human FcγRIIA induces anaphylactic and allergic reactions. *Blood* 2012; 119:2533-44.
60. Khodoun M, Strait R, Orekov T, Hogan S, Karasuyama H, Herbert DR, et al. Peanuts can contribute to anaphylactic shock by activating complement. *J Allergy Clin Immunol* 2009; 123:342-51.
61. Liu E, Moriyama H, Abiru N, Miao D, Yu L, Taylor RM, et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. *J Clin Invest* 2002; 110:1021-7.
62. Arias K, Baig M, Colangelo M, Chu D, Walker T, Goncharova S, et al. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. *J Allergy Clin Immunol* 2009; 124:307-14, 14 e1-2.
63. Cloutier N, Allaey S, Marcoux G, Machlus KR, Mailhot B, Zufferey A, et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. *Proc Natl Acad Sci U S A* 2018; 115:E1550-E9.
64. Khodoun MV, Strait R, Armstrong L, Yanase N, Finkelman FD. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. *Proc Natl Acad Sci U S A* 2011; 108:12413-8.
65. Kalesnikoff J, Galli SJ. New developments in mast cell biology. *Nat Immunol* 2008; 9:1215-23.
66. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. *Immunity* 2014; 41:21-35.
67. Janssens AS, Heide R, den Hollander JC, Mulder PG, Tank B, Oranje AP. Mast cell distribution in normal adult skin. *J Clin Pathol* 2005; 58:285-9.
68. Strait RT, Morris SC, Finkelman FD. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and FcγRIIb cross-linking. *J Clin Invest* 2006; 116:833-41.
69. Strait RT, Mahler A, Hogan S, Khodoun M, Shibuya A, Finkelman FD. Ingested allergens must be absorbed systemically to induce systemic anaphylaxis. *J Allergy Clin Immunol* 2011; 127:982-9 e1.
70. Kucuk ZY, Strait R, Khodoun MV, Mahler A, Hogan S, Finkelman FD. Induction and suppression of allergic diarrhea and systemic anaphylaxis in a murine model of food allergy. *J Allergy Clin Immunol* 2012; 129:1343-8.

71. Tacquard C, Collange O, Gomis P, Malinovsky JM, Petitpain N, Demoly P, et al. Anaesthetic hypersensitivity reactions in France between 2011 and 2012: the 10th GERAP epidemiologic survey. *Acta Anaesthesiol Scand* 2017; 61:290-9.
72. Baldo BA, Fisher MM. Substituted ammonium ions as allergenic determinants in drug allergy. *Nature* 1983; 306:262-4.
73. Pichler WJ. Anaphylaxis to drugs: Overcoming mast cell unresponsiveness by fake antigens. *Allergy* 2020.
74. Ansotegui IJ, Melioli G, Canonica GW, Caraballo L, Villa E, Ebisawa M, et al. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. *World Allergy Organ J* 2020; 13:100080.
75. Broyles AD, Banerji A, Barmettler S, Biggs CM, Blumenthal K, Brennan PJ, et al. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. *J Allergy Clin Immunol Pract* 2020; 8:S16-S116.
76. van der Poorten MM, Van Gasse AL, Hagendorens MM, Faber MA, De Puyseleir L, Elst J, et al. Serum specific IgE antibodies in immediate drug hypersensitivity. *Clin Chim Acta* 2020; 504:119-24.
77. Van Der Poorten MM, Molina-Molina G, Van Gasse AL, Hagendorens MM, Faber MA, De Puyseleir L, et al. Application of specific-to-total IgE ratio does not benefit diagnostic performance of serologic testing for rocuronium allergy. *Br J Anaesth* 2020; 125:e443-e6.
78. Anderson J, Green S, Capon M, Krupowicz B, Li J, Fulton R, et al. Measurement of pholcodine-specific IgE in addition to morphine-specific IgE improves investigation of neuromuscular blocking agent anaphylaxis. *Br J Anaesth* 2020; 125:e450-e2.
79. Goyard S, Balbino B, Chinthrajah RS, Lyu SC, Janin YL, Bruhns P, et al. A highly sensitive bioluminescent method for measuring allergen-specific IgE in microliter samples. *Allergy* 2020.
80. Vitte J, Amadei L, Gouitaa M, Mezouar S, Zieleskiewicz L, Albanese J, et al. Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study. *Allergy* 2019; 74:1157-65.
81. Banerji A, Bhattacharya G, Huebner E, Fu X, Camargo CA, Jr., Guyer A, et al. Perioperative Allergic Reactions: Allergy Assessment and Subsequent Anesthesia. *J Allergy Clin Immunol Pract* 2020.
82. Elst J, Sabato V, Hagendorens MM, van Houdt M, Faber MA, Bridts CH, et al. Measurement and Functional Analysis of the Mas-Related G Protein-Coupled Receptor MRGPRX2 on Human Mast Cells and Basophils. *Methods Mol Biol* 2020; 2163:219-26.
83. Lansu K, Karpiak J, Liu J, Huang XP, McCorvy JD, Kroeze WK, et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2. *Nat Chem Biol* 2017; 13:529-36.
84. Ebo DG, Van der Poorten ML, Elst J, Van Gasse AL, Mertens C, Bridts C, et al. Immunoglobulin E cross-linking or MRGPRX2 activation: clinical insights from rocuronium hypersensitivity. *Br J Anaesth* 2021; 126:e27-e9.
85. Elst J, Sabato V, Mertens C, Garvey LH, Ebo DG. Association between mutated Mas-related G protein-coupled receptor-X2 and rocuronium-induced intraoperative anaphylaxis. Comment on *Br J Anaesth* 2020; 125: e446-e448. *Br J Anaesth* 2020; 125:e448-e50.
86. Alkanfari I, Gupta K, Jahan T, Ali H. Naturally Occurring Missense MRGPRX2 Variants Display Loss of Function Phenotype for Mast Cell Degranulation in Response to

682 Substance P, Hemokinin-1, Human beta-Defensin-3, and Icatibant. *J Immunol* 2018;
683 201:343-9.

684 87. Ebo DG, Bridts CH, Mertens CH, Sabato V. Principles, potential, and limitations of ex
685 vivo basophil activation by flow cytometry in allergology: A narrative review. *J Allergy*
686 *Clin Immunol* 2020.

687 88. Dewachter P, Chollet-Martin S, Mouton-Faivre C, de Chaisemartin L, Nicaise-Roland P.
688 Comparison of Basophil Activation Test and Skin Testing Performances in NMBA
689 Allergy. *J Allergy Clin Immunol Pract* 2018.

690 89. Granger V, Taille C, Roach D, Letuve S, Dupin C, Hamidi F, et al. Circulating neutrophil
691 and eosinophil extracellular traps are markers of severe asthma. *Allergy* 2020; 75:699-
692 702.

693 90. Gao Y, Han Y, Zhang X, Fei Q, Qi R, Hou R, et al. Penicillin causes non-allergic
694 anaphylaxis by activating the contact system. *Sci Rep* 2020; 10:14160.

695 91. Hogwood J, Naggi A, Torri G, Page C, Rigsby P, Mulloy B, et al. The effect of increasing
696 the sulfation level of chondroitin sulfate on anticoagulant specific activity and
697 activation of the kinin system. *PLoS One* 2018; 13:e0193482.

698 92. Daguet A, Watier H. 2nd Charles Richet et Jules Hericourt workshop: therapeutic
699 antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France. *MAbs* 2011; 3:417-
700 21.

701 93. Steinke JW, Platts-Mills TA, Commins SP. The alpha-gal story: lessons learned from
702 connecting the dots. *J Allergy Clin Immunol* 2015; 135:589-96; quiz 97.

703 94. Sanchez-Lopez J, Araujo G, Cardona V, Garcia-Moral A, Casas-Saucedo R, Guilarte M,
704 et al. Food-dependent NSAID-induced hypersensitivity (FDNIH) reactions: Unraveling
705 the clinical features and risk factors. *Allergy* 2020.

706 95. Fernandez J, Ruano-Zaragoza M, Blanca-Lopez N. Omalizumab and other biologics in
707 drug desensitization. *Curr Opin Allergy Clin Immunol* 2020; 20:333-7.

708 96. Orengo JM, Radin AR, Kamat V, Badithe A, Ben LH, Bennett BL, et al. Treating cat allergy
709 with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. *Nat*
710 *Commun* 2018; 9:1421.

711 97. Vultaggio A, Matucci A, Nencini F, Bormioli S, Vivarelli E, Maggi E. Mechanisms of Drug
712 Desensitization: Not Only Mast Cells. *Front Pharmacol* 2020; 11:590991.

713 98. McDonnell NJ, Pavy TJ, Green LK, Platt PR. Sugammadex in the management of
714 rocuronium-induced anaphylaxis. *Br J Anaesth* 2010; 106:199-201.

715 99. Leysen J, Bridts CH, De Clerck LS, Ebo DG. Rocuronium-induced anaphylaxis is probably
716 not mitigated by sugammadex: evidence from an in vitro experiment. *Anaesthesia*
717 2011; 66:526-7.

718 100. Raft J, Leclercq M, Longrois D, Meistelman C. [Fast recovery of haemodynamic and
719 ventilatory functions after sugammadex bolus following rocuronium-induced
720 anaphylactic shock refractory to conventional treatment]. *Ann Fr Anesth Reanim* 2012;
721 31:158-61.

722 101. Spoerl D, D'Incau S, Roux-Lombard P, Harr T, Czarnetzki C. Non-IgE-Dependent
723 Hypersensitivity to Rocuronium Reversed by Sugammadex: Report of Three Cases and
724 Hypothesis on the Underlying Mechanism. *Int Arch Allergy Immunol* 2016; 169:256-
725 62.

726 102. Savic L, Savic S, Hopkins PM. Anaphylaxis to sugammadex. *Anaesth Intensive Care*
727 2014; 42:7-9.

103. Ebo DG, Baldo BA, Van Gasse AL, Mertens C, Elst J, Sermeus L, et al. Anaphylaxis to sugammadex-rocuronium inclusion complex: An IgE-mediated reaction due to allergenic changes at the sugammadex primary rim. *J Allergy Clin Immunol Pract* 2020; 8:1410-5 e3.
104. Orihara M, Takazawa T, Horiuchi T, Sakamoto S, Nagumo K, Tomita Y, et al. Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study. *Br J Anaesth* 2020; 124:154-63.

FIGURES

Figure 1. Relative drug sizes implicated in drug-induced anaphylaxis: size does not matter. Schematic representations of poly ethylene glycol (Image Credit: StudioMolekuul/Shutterstock.com), IgG, enzyme (Image credit; [PDB 9LYZ](#)), and chemical structures of indicated drugs and contrast agents. Dots represent the relative size of the depicted small molecules (<1 kDa) compared to those of PEG, IgG and enzymes.

750

751

752

753

754

755

756

757

758

759

760

761

Figure 2. Potential pathways in drug-induced anaphylaxis. Once administrated a drug can be bound by (a) drug-specific IgE antibodies, pre-bound on their high-affinity IgE receptor (FceRI)-expressing mast cells and basophils, leading to their release of anaphylactogenic mediators, histamine and to some extent PAF (*Note: human mast cells are thought to make little or no serotonin*); (b) drug-specific IgG antibodies, forming drug-IgG immune complexes that can bind to their low-affinity IgG receptor (FcγR)-expressing neutrophils (e.g. FcγRIIA and FcγRIIIB) and monocyte/macrophages (e.g. FcγRIIA and FcγRIIIA), leading to their release of PAF, and to FcγRIIA-platelets leading to their release of serotonin; (c) mast cell-expressed MRGPRX2 if that drug has affinity for this receptor, leading to mast cell degranulation and histamine and PAF release. The thickness of the green-colored arrows represent their contribution to the indicated mediator release.

763

764 **Figure 3. Mechanisms of IgG-induced neutrophil activation during drug anaphylaxis.** The
 765 classical and historical pathway of anaphylaxis is based on mediator release by mast cells and
 766 basophils activated by the engagement of FcεRI after their interaction with a drug/anti-drug IgE
 767 immune complex (IC). A second pathway was recently demonstrated both in mice and human.
 768 The drug can react with specific IgG and form an IC that binds to several FcγRs at the neutrophil
 769 surface and activate the cell. In addition to reactive oxygen species (ROS) and proteases release
 770 such as neutrophil elastase (NE) and myeloperoxidase (MPO), neutrophils release platelet
 771 activating factor (PAF) and neutrophil extracellular traps (NETs), also involved in anaphylaxis
 772 clinical manifestations. The release of NETs is the consequence of ROS production, in
 773 particular due to mitochondrial-derived ROS (mROS) production and peptidyl arginase
 774 deiminase 4 (PAD4) activation leading to chromatin decondensation, nuclear membrane
 775 disruption and chromatin extracellular release.
 776